AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Adaptive Biotechnologies Corp (NASDAQ:ADPT)
22.92 USD
+0.820 3.710%Sponsored Reports
Loading...
| Previous Close (in USD) | 22.1 |
|---|---|
| Change | +0.820 3.710% |
| 52 W H/L (in USD) | 20.760/7.160 |
| EBITDA (in USD) | -39.29M |
| PE Ratio | -- |
| Volume | 3230774 |
| Diluted Eps TTM | -0.39 |
| Total Assets (in USD) | 512.736M |
|---|---|
| Total Liabilities (in USD) | 287.735M |
| Revenue TTM (in USD) | 276.976M |
| Cash (in USD) | 70.495M |
| Market Cap (in USD) | 2,245.051 M |
| Revenue Per Share TTM | 1.826 |
| Gross Profit TTM (in USD) | 205.617M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
1165 Eastlake Avenue East, Seattle, WA, United States, 98109
206 659 0067
Employees: 624
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Chad M. Robins M.B.A, M.B.A. | Co-Founder, CEO & Chairman | 1974 |
| 2. | Ms. Julie Rubinstein | Pres | 1972 |
| 3. | Dr. Harlan S. Robins Ph.D. | Co-Founder & Chief Scientific Officer | 1973 |
| 4. | Mr. Nitin Sood | Chief Commercial Officer of MRD | NA |
| 5. | Mr. Christopher Carlson Ph.D. | Founder | NA |
| 6. | Mr. Tycho W. Peterson | Chief Financial Officer | NA |
| 7. | Dr. Mark Adams Ph.D. | Chief Operating Officer | 1967 |
| 8. | Mr. Kyle Piskel | Principal Accounting Officer | 1984 |
| 9. | Yi Zhou | Chief Technical Officer | NA |
| 10. | Karina Calzadilla | VP of Investor Relations | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-1.160 2.253% | 51.06 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.820 1.602% | 51.2 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.380 0.078% | 483.51 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-2.250 0.331% | 676.05 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -59.457M | -159.595M | -225.304M | -200.368M | -207.298M |
| Minority Interest | -0.042M | 0.103M | 0.069M | 0.177M | -0.019M |
| Net Income | -59.499M | -159.492M | -225.25M | -142.464M | -205.611M |
| Selling General Administrative | 72.701M | 72.806M | 83.934M | 88.527M | 74.502M |
| Gross Profit | 205.617M | 106.877M | 94.723M | 127.399M | 105.043M |
| Reconciled Depreciation | 17.833M | 19.256M | 22.125M | 20.92M | 13.953M |
| Ebit | -47.679M | -148.015M | -211.504M | -200.186M | -208.966M |
| Ebitda | -29.846M | -128.759M | -189.273M | -194.431M | -207.267M |
| Depreciation And Amortization | 17.833M | 19.256M | 22.231M | 5.755M | 1.699M |
| Operating Income | -57.123M | -162.549M | -227.035M | -200.186M | -208.966M |
| Other Operating Expenses | 334.099M | 341.506M | 397.311M | 385.494M | 363.31M |
| Interest Expense | 11.778M | 11.58M | 13.8M | 4.238M | 1.668M |
| Tax Provision | - | - | - | - | 0M |
| Interest Income | 9.444M | 14.534M | 13.52M | 4.056M | 1.668M |
| Net Interest Income | -2.334M | 2.954M | -0.853M | -0.182M | 1.668M |
| Income Tax Expense | - | - | -0.054M | -57.904M | -1.687M |
| Total Revenue | 276.976M | 178.957M | 170.276M | 185.308M | 154.344M |
| Total Operating Expenses | 262.74M | 269.426M | 321.758M | 327.585M | 314.009M |
| Cost Of Revenue | 71.359M | 72.08M | 75.553M | 57.909M | 49.301M |
| Total Other Income Expense Net | -2.334M | 2.954M | 1.731M | -0.182M | 1.668M |
| Net Income From Continuing Ops | -59.457M | -159.595M | -196.006M | -200.368M | -207.298M |
| Net Income Applicable To Common Shares | - | - | - | -200.191M | -207.279M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 512.736M | 539.376M | 661.134M | 856.617M | 923.344M |
| Intangible Assets | 1.726M | 3.425M | 5.128M | 6.827M | 8.526M |
| Other Current Assets | 13.02M | 11.287M | 10.37M | 9.44M | 13.015M |
| Total Liab | 287.735M | 336.891M | 352.856M | 392.519M | 319.242M |
| Total Stockholder Equity | 218.793M | 202.709M | 308.399M | 464.165M | 603.992M |
| Other Current Liab | 24.692M | 24.684M | 22.282M | 28.359M | 24.985M |
| Common Stock | 0.015M | 0.014M | 0.014M | 0.014M | 0.014M |
| Capital Stock | 0.015M | 0.014M | 0.014M | 0.014M | 0.014M |
| Retained Earnings | -1363.323M | -1303.824M | -1144.332M | -919.082M | -718.891M |
| Good Will | 118.972M | 118.972M | 118.972M | 118.972M | 118.972M |
| Other Assets | - | - | - | 4.462M | 3.013M |
| Cash | 70.495M | 47.92M | 65.064M | 90.03M | 139.065M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 89.915M | 98.053M | 88.015M | 109.788M | 113.807M |
| Current Deferred Revenue | 45.194M | 55.689M | 48.63M | 64.115M | 80.46M |
| Net Debt | 210.089M | 41.467M | 164.368M | 17.972M | -27.325M |
| Short Term Debt | 13.562M | 10.239M | 9.384M | 9.23M | 5.055M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 280.584M | 89.387M | 229.432M | 108.002M | 111.74M |
| Other Stockholder Equity | 1581.848M | 1506.353M | 1452.502M | 1387.349M | 1324.006M |
| Property Plant Equipment | - | - | - | 83.447M | 85.262M |
| Total Current Assets | 300.185M | 283.752M | 410.188M | 562.146M | 402.748M |
| Long Term Investments | 13.234M | 33.66M | - | 0M | 217.145M |
| Short Term Investments | 156.485M | 174.374M | 281.337M | 408.166M | 213.996M |
| Net Receivables | 50.365M | 41.731M | 38.969M | 40.057M | 17.409M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 9.82M | 8.44M | 14.448M | 14.453M | 19.263M |
| Accounts Payable | 6.467M | 7.265M | 7.719M | 8.084M | 3.307M |
| Accumulated Other Comprehensive Income | 0.253M | 0.166M | 0.215M | -4.116M | -1.137M |
| Non Currrent Assets Other | 1.207M | 5.184M | -1.537M | 4.462M | 3.013M |
| Non Current Assets Total | 212.551M | 255.624M | 250.946M | 294.471M | 520.596M |
| Capital Lease Obligations | 79.148M | 89.387M | 98.772M | 108.002M | 111.74M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 40.909M | 77.792M | 28.896M | 2.905M | 242.956M |
| Total Cashflows From Investing Activities | 37.95M | 77.792M | 129.647M | 2.905M | 181.21M |
| Total Cash From Financing Activities | 30.403M | 0.241M | 2.245M | 132.265M | 27.146M |
| Net Income | -59.499M | -159.595M | -225.25M | -200.368M | -207.298M |
| Change In Cash | 22.367M | -17.179M | -24.966M | -48.775M | 15.629M |
| Begin Period Cash Flow | 50.817M | 67.996M | 90.03M | 141.203M | 125.574M |
| End Period Cash Flow | 73.184M | 50.817M | 65.064M | 92.428M | 141.203M |
| Total Cash From Operating Activities | -45.986M | -95.212M | -156.324M | -183.945M | -192.727M |
| Depreciation | 17.833M | 19.256M | 22.231M | 20.92M | 13.953M |
| Other Cashflows From Investing Activities | - | - | -0M | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -0.998M | 1.938M | -2.838M | 0.817M | -5.2M |
| Sale Purchase Of Stock | - | - | - | 7.89M | 26.717M |
| Other Cashflows From Financing Activities | 30.403M | 0.241M | 2.245M | 124.375M | 27.146M |
| Capital Expenditures | 2.959M | 3.664M | 10.697M | 16.349M | 61.746M |
| Change In Working Capital | -57.767M | -17.454M | -46.183M | -71.546M | -56.816M |
| Other Non Cash Items | 19.797M | 8.971M | 92.878M | 11.572M | 6.95M |
| Free Cash Flow | -48.945M | -98.876M | -167.021M | -200.294M | -254.473M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 3 months ago | 4615320 |
| 2. | iShares Russell 2000 ETF | 3 months ago | 3626190 |
| 3. | ARK Genomic Revolution ETF | 3 months ago | 2023448 |
| 4. | ARK Genomic Revolution | 3 months ago | 2002912 |
| 5. | Lord Abbett Developing Growth A | 4 months ago | 1697752 |
| 6. | Vanguard Small Cap Index | 3 months ago | 1690428 |
| 7. | US Small-Cap Growth II Equity Comp | 6 months ago | 1645314 |
| 8. | Xtrackers MSCI World Swap ETF 1C | 6 months ago | 1590690 |
| 9. | Fidelity Small Cap Index | 5 months ago | 1446328 |
| 10. | Alger Small Cap Focus Composite | 5 months ago | 1391226 |
| 11. | Alger Small Cap Focus I | 5 months ago | 1391226 |
| 12. | Amova ARK Pstv Chg Innovt P JPY Acc | 4 months ago | 1377807 |
| 13. | Vanguard Institutional Extnd Mkt Idx Tr | 3 months ago | 1326845 |
| 14. | iShares Russell 2000 Growth ETF | 3 months ago | 1221787 |
| 15. | BNP Paribas US Small Cap ClassicC | 4 months ago | 1220271 |
| 16. | Columbia Acorn Inst | 4 months ago | 1148404 |
| 17. | Harbor Small Cap Growth Instl | 3 months ago | 1145000 |
| 18. | Westfield Capital Mgt Co Sm-Cap Gr Eq | 3 months ago | 1145000 |
| 19. | iShares Biotechnology ETF | 3 months ago | 1108297 |
| 20. | T. Rowe Price Integrated US SmCapGrEq | 6 months ago | 1101637 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Viking Global Investors LP | 6 months ago | 29993708 |
| 2. | BlackRock Inc | 9 months ago | 13357977 |
| 3. | Vanguard Group Inc | 6 months ago | 11282152 |
| 4. | Ameriprise Financial Inc | 9 months ago | 5971706 |
| 5. | Westfield Capital Management Company, L.P. | 6 months ago | 4060481 |
| 6. | Sumitomo Mitsui Trust Group Inc | 9 months ago | 3650646 |
| 7. | Geode Capital Management, LLC | 6 months ago | 3511855 |
| 8. | Lord, Abbett & Co LLC | 6 months ago | 3080759 |
| 9. | State Street Corp | 9 months ago | 3079282 |
| 10. | The Goldman Sachs Group Inc | 6 months ago | 2902269 |
| 11. | Driehaus Capital Management LLC | 6 months ago | 2760387 |
| 12. | Jennison Associates LLC | 6 months ago | 2674668 |
| 13. | Arrowstreet Capital Limited Partnership | 6 months ago | 2422089 |
| 14. | Fred Alger Management, LLC | 6 months ago | 2245418 |
| 15. | Wellington Management Company LLP | 6 months ago | 2165327 |
| 16. | ARK Investment Management LLC | 6 months ago | 2138960 |
| 17. | Amova Asset Management Americas, Inc | 6 months ago | 1947963 |
| 18. | D. E. Shaw & Co LP | 6 months ago | 1902685 |
| 19. | Aristotle Atlantic Partners, LLC | 6 months ago | 1842444 |
| 20. | Blue Water Life Science Advisors, LLC | 6 months ago | 1765145 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...